Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 75.3% in April

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 554,017 shares, a growth of 75.3% from the March 31st total of 316,118 shares. Based on an average trading volume of 434,687 shares, the days-to-cover ratio is presently 1.3 days. Currently, 4.2% of the company’s stock are sold short.

Insider Buying and Selling

In related news, major shareholder Michael C. Skaff acquired 1,353,625 shares of Vivos Therapeutics stock in a transaction on Tuesday, March 31st. The shares were purchased at an average cost of $1.34 per share, for a total transaction of $1,813,857.50. Following the purchase, the insider directly owned 1,353,625 shares of the company’s stock, valued at $1,813,857.50. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.10% of the stock is owned by company insiders.

Institutional Trading of Vivos Therapeutics

Several hedge funds have recently added to or reduced their stakes in VVOS. XTX Topco Ltd bought a new stake in Vivos Therapeutics during the 2nd quarter valued at $65,000. B. Riley Wealth Advisors Inc. bought a new stake in Vivos Therapeutics during the 2nd quarter valued at $220,000. Connective Capital Management LLC bought a new stake in Vivos Therapeutics during the 3rd quarter valued at $620,000. Acorn Wealth Advisors LLC bought a new stake in Vivos Therapeutics during the 4th quarter valued at $30,000. Finally, DRW Securities LLC increased its stake in Vivos Therapeutics by 179.5% during the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after buying an additional 74,441 shares during the period. Institutional investors own 26.35% of the company’s stock.

Vivos Therapeutics Price Performance

VVOS stock opened at $0.84 on Monday. The company has a quick ratio of 0.24, a current ratio of 0.24 and a debt-to-equity ratio of 3.31. Vivos Therapeutics has a fifty-two week low of $0.82 and a fifty-two week high of $7.95. The firm’s 50-day simple moving average is $1.29 and its 200 day simple moving average is $1.89. The stock has a market cap of $11.36 million, a PE ratio of -0.41 and a beta of 6.93.

Vivos Therapeutics (NASDAQ:VVOS) last issued its quarterly earnings data on Wednesday, April 15th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.08). The business had revenue of $3.82 million during the quarter, compared to the consensus estimate of $7.10 million. Vivos Therapeutics had a negative return on equity of 849.22% and a negative net margin of 121.37%.During the same period last year, the company earned ($2.22) earnings per share. As a group, sell-side analysts predict that Vivos Therapeutics will post -1.45 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Monday, April 20th. Ascendiant Capital Markets reduced their price objective on shares of Vivos Therapeutics from $5.50 to $3.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Finally, HC Wainwright reduced their price objective on shares of Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating on the stock in a research note on Friday, April 17th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $2.58.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.